Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: an observational study

The American Cancer Society estimates that in 2014, there will be over 12,000 new cases of invasive cervical cancer diagnosed in the United States and over 4,000 women will die from this disease [1]. Human papillomavirus (HPV), the most common sexually transmitted infection [2, 3], has been shown to be necessary to cause cervical cancer [4‐6]. Recognition of this link led to the development of vaccines protecting against infection with certain high-risk types of HPV. There are currently two HPV vaccines available: Merck’s Gardasil® vaccine [7], proved highly effective in preventing the highest prevalence HPV types 16 and 18 (which cause up to 70 % of all cervical cancers), as well as HPV types 6 and 11 (which cause about 90 % of genital warts) [4, 8‐10]; and GlaxoSmithKline’s Cervarix® vaccine [11], targeting the two most common oncogenic HPV types (16 and 18) [4, 10].

In 2006, the Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) recommended a 3-dose HPV vaccination series as a routine vaccine for girls age 11–12 years old [12]. Vaccine administration is optimal at this age because adolescents have the best immunoresponse to the vaccine and likely have not yet been exposed to the virus [12]. However, the ACIP also recommended the HPV vaccination series as a catch-up vaccine for young women age 13–26 years old [12]. Additionally, these recommendations have been extended to include males. It is hypothesized that with good vaccination coverage, the prevalence of HPV and HPV-associated cancers will decline [5, 12‐14].

Despite this opportunity for cervical cancer prevention, HPV vaccination rates are low in the United States. In 2013, just 57.3 % of adolescent girls age 13–17 years old had received one dose of the vaccine, and only 37.6 % had completed the three-dose series [15]. Coverage is especially poor in Utah, with just 44.3 % of Utah adolescent girls initiating the vaccine, and 20.5 % completing the 3-dose series [15]. Most recent data indicates that uptake is the worst among young women: only 34.5 % of women age 19–26 years old report receiving at least one dose of the HPV vaccine [16]. State-specific data for this age group is unavailable. In spite of this low HPV vaccine coverage, recommendations from physicians remain suboptimal for all age groups [17].

While the choice whether or not to vaccinate adolescent usually falls to their parents, young women who are eligible to receive the vaccine are able to make the decision for themselves. These women are responsible for their own health, so their attitudes towards receiving the HPV vaccine and their decision-making processes may be different from those of the parents of young adolescents. There have been many studies on women’s beliefs and behaviors related to the HPV vaccine, but few studies have specifically focused on a state with low HPV vaccine initiation and completion rates [18‐25].

The purpose of this study is to assess the demographic and attitudinal factors associated with HPV initiation and completion among 18–26 year old women in Utah. Our goal is to generate information to develop intervention programs to increase HPV vaccination in this age group in Utah.

This study was approved by the University of Utah Institutional Review Board.

A total of 84 of 993 surveys (8.5 %) from the first wave and 244 of 901 surveys (27.1 %) from the second wave were returned for a total of 328 of 1,983 returned (16.5 %). Three participants were excluded: two for having an age out of range and one for incompleteness of the questionnaire. The remaining 325 were included in the final analysis. There were no statistically significant differences between the two survey waves, and the only difference between wave one and wave two was wave two included a small incentive, but otherwise was drawn from the same population. Therefore, the two waves were pooled for the analysis.

Of these 325 participants, 204 (62.8 %) had initiated the vaccine series and 159 (48.9 %) had completed the 3-dose series. Of the 45 who had initiated, but not completed the vaccine series, 31 (70.5 %) said they intended to complete the series and 13 (29.6 %) said they did not (one missing). The mean age for those who initiated the vaccine was 22.4 years (s.d. 2.4 years), for those who completed the 3-dose series was 22.4 years (s.d. 2.4 years), and for those who did not receive any vaccine doses was 23.3 years (s.d. 2.3 years). Participant characteristics are presented in Table 1 and participants’ HPV vaccine related knowledge and attitudes are presented in Table 2.

The factor analysis produced a total of seven attitude factors with good inter-item correlation, presented in Table 3. Table 4 shows the significant univariate predictors of vaccine initiation were lower age vs. older age: OR = 1.18 per lower year [95 % CI: 1.07–1.30]; marital status (being unmarried vs. married): OR = 3.62 [95 % CI: 2.18–5.99]; not practicing vs. practicing organized religion: OR = 2.4 [95 % CI: 1.49–4.0]; knowledge of HPV transmission: OR = 6.29 [95 % CI: 3.46–11.44]; known connection between HPV and cervical cancer: OR = 3.90 [95 % CI: 2.21–6.89]; known importance of vaccine (to help prevent cervical cancer): OR = 2.45 [95 % CI: 1.79–3.36]; strength of doctor recommendation: OR = 1.86 per Likert scale unit [95 % CI: 1.27–2.70]; and a binary indicator of whether a physician’s recommendation is influential: OR = 1.70 [95 % CI: 1.38–2.09]. These variables were all also significant predictors of completion of the 3-dose series (see Table 4). Minimal sufficient adjustment sets were derived from application of the DAG (see Fig. 2) to produce subsets of variables adequate to control for potential confounding. These subsets were used to produce adjusted estimates (see Table 4).

The main reasons for not intending to initiate or complete the vaccine were waiting for more information/vaccine too new (n = 38), married or monogamous relationship (n = 36), cost of vaccine or unsure if insurance covers vaccine (n = 23), concern of side effects (n = 18), not sexually active (n = 14), and vaccine inconvenience (n = 7) (see Fig. 3).

The HPV vaccine has been available in the United States for eight years, yet only one third of adolescents have been fully immunized with all three recommended doses, and only one third of older eligible women (age 18–26 years old) have received just one dose of the 3-dose series [12, 15, 16]. HPV vaccine coverage varies substantially among states, with Utah having some of the lowest coverage rates in the U.S. [15]. Clearly, the Unites States is far from the Healthy People 2020 target of 80 % HPV vaccine coverage among eligible females, indicating an urgent need for interventions [15].

Resources are currently available to help increase HPV vaccination in Utah. In April 2007, Jon Huntsman, Sr. donated $1 million to the Utah Department of Health to educate Utahans about cervical cancer and provide low cost HPV vaccines to eligible women [36]. An additional $25,000 allocated by the Utah legislature was used for a public awareness media campaign and to inform physicians and other health care professionals about the HPV vaccine [36]. Additionally, the HPV vaccine is available for free or at low cost for girls age 9–18 years old through the Vaccines for Children Program and may be available for free or at low cost for women age 19–26 years old who have no insurance or insurance that does not pay for the vaccine thanks to Vaccine Patient Assistance Programs [37, 38]. The results of our study can help to focus these funds and resources to reach women who have not yet initiated and/or completed the HPV vaccination series.

Our study of young women age 18–26 years old found several correlates of vaccine initiation and completion that may be useful for future public health interventions for this population. Among these correlates were lower age, awareness of HPV transmission, knowledge of its connection to cervical cancer, belief in the importance of the HPV vaccine, and a physician recommendation (especially a strong recommendation) (Additional file 1: Figure S1). Marital status (being unmarried), practicing organized religion, and higher education were also significant predictors of vaccine initiation and completion. Cost, being in a monogamous relationship, and novelty of the vaccine were the main barriers against vaccination.

These findings echo previous studies that identified knowledge-attitude-practice gaps in the context of the HPV vaccine [39]. The differences we found between vaccinated women and unvaccinated women regarding risk beliefs (i.e., the vaccine is not personally relevant because they are in a monogamous relationship and the vaccine is too new and more information is needed) help explain why increasing uptake of the HPV vaccine requires targeted risk communication strategies [39]. Additionally, our study confirms one of the most ubiquitous finding in HPV vaccine research: the importance of a consistent and strong recommendation of the HPV vaccine from healthcare providers [23, 40, 41]. However, our findings run counter to an earlier study showing no association between marital status in their multivariable analysis [23]. This difference could be due to the particular interplay between marriage, age, and religiosity in the state of Utah.

There are limitations to the generalizability of the current study. The majority of participants were White/Caucasian (>80 %), had access to healthcare, and response rates were higher in the vaccinated vs. the unvaccinated, which may have introduced unmeasured response bias. Furthermore, cross-sectional study design prohibits assessment of causal relationships.

The implications of these findings may help inform policies regarding HPV vaccination education among young women. For example, without this information programs might focus on awareness [36, 42‐44], but the results of this study illustrate that the significance of awareness of HPV as a predictor of vaccine uptake has diminished over time and that programs should now focus on other variables (for example, strong and consistent physician recommendations). Additionally, our findings indicate the need for discussions of risk assessment tailored to the young adult population since young women are sure of their sexual behavior in a way parents may not be of their children’s. These interventions may use our results to take into account a patient’s education, religious affiliation and relationship status when having such conversations. Future research is needed to assess the impact these tailored interventions would have on bolstering HPV vaccination rates in the low vaccination state of Utah.

ACIP, advisory committee on immunization practices; CDC, centers for disease control; DAG, directed acyclic graph; HBM, health belief model; HPV, human papillomavirus; IRB, institutional review board; OR, odds ratio; SCM, social cognitive model